In a report published Friday, Brean Capital analyst Gene Mack reiterated a Buy rating on Celgene Corporation CELG, and raised the price target from $153.00 to $191.00.
In the report, Brean Capital noted, “CELG reported 3Q13 of $1.56 per share, beating our $1.50 estimate and inline with consensus of $1.55. Management updated guidance for FY13, reiterated sales guidance of $6.2B but increased EPS to $5.90-5.95 from $5.80-5.90 per share. We are rolling our P/E based price target out to our 2014 EPS estimate of $7.63 and increasing our multiple to 25x, which increases our PT to $191, due to the potential for Revlimid label expansion and Apremilast approval as well as continued Abraxane growth throughout 2014.”
Celgene Corporation closed on Thursday at $157.96.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in